目的 探究沙利度胺片聯(lián)合CHOP方案治療外周T細胞淋巴瘤的臨床療效。方法 選取2015年9月-2016年9月鄭州頤和醫(yī)院收治的外周T細胞淋巴瘤患者53例，按照隨機數(shù)表法隨機分為對照組（27例）和治療組（26例）。對照組給予CHOP方案治療：第1天靜脈注射注射用環(huán)磷酰胺750 mg/m²；注射用硫酸長春新堿1.4 mg/m²；鹽酸表柔比星注射液50 mg/m²；同時第1~5天口服醋酸潑尼松片，10 mg/d。治療組在對照組基礎上口服沙利度胺片，起始劑量為50 mg/次，2次/d，每周劑量增加50 mg/次直至200 mg/次。兩組均以21 d為1個療程，共治療8個療程。觀察兩組的臨床療效，比較兩組的精氨酸酶1（Arg-1）、血管內皮生長因子（VEGF）、誘生型一氧化氮合成酶（iNOS）水平和不良反應情況。結果 治療后，對照組和治療組的總有效率分別為62.96%、84.62%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，治療組Arg-1、VEGF、iNOS水平均顯著下降，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療組這些觀察指標的下降程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。對照組和治療組骨髓抑制發(fā)生率分別為55.56%、19.23%，胃腸道不良反應發(fā)生率分別為59.26%、19.23%，肝臟損害發(fā)生率分別為37.03%、26.92%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 沙利度胺片聯(lián)合CHOP方案治療外周T細胞淋巴瘤具有較好的臨床療效，可降低Arg-1、VEGF、iNOS水平，安全性較好，具有一定的臨床推廣應用價值。

Objective To investigate the clinical effect of Thalidomide Tablets combined with CHOP regimen in treatment of lymphoma peripheral T cell. Methods Patients (53 cases) with lymphoma peripheral T cell in Zhengzhou Yihe Hospital Affiliated to Henan University from September 2015 to September 2016 were randomly divided into the control group (27 cases) and the treatment group (26 cases) according to the random number table method. Patients in the control group were given CHOP regimen. Patients in the control group were iv administered with Ifosfamide for injection 750 mg/m² at the first day. Patients in the control group were iv administered with Vincristine Sulfate for injection 1.4 mg/m² at the first day. Patients in the control group were iv administered with Epirubicin Hydrochloride Injection for injection 50 mg/m² at the first day. And Patients in the control group were po administered with Prednisone Acetate Tablets 10 mg/d on day 1 - 5. Patients in the treatment group were po administered with Thalidomide Tablets on the basis of the control group, starting dosage 50 mg/time, increase of 50 mg/time weekly until 200 mg/time. A course of treatment was 21 d in two groups, treatment of 8 courses. After treatment, the clinical efficacies were evaluated, and Arg-1, VEGF, iNOS levels, and adverse reactions in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 62.96% and 84.62%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of Arg-1, VEGF, iNOS in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). The incidence of bone marrow suppression in the control and treatment groups were 55.56% and 19.23%, respectively. The incidence of gastrointestinal reactions in the control and treatment groups were 59.26% and 19.23%, respectively. The incidence of liver damage in the control and treatment groups were 37.03% and 26.92%, respectively, and there was difference between two groups (P < 0.05). Conclusion Thalidomide Tablets combined with CHOP regimen has clinical curative effect in treatment of lymphoma peripheral T cell, can decrease the levels of Arg-1, VEGF, and iNOS, with good safety, which has a certain clinical application value.